FIERCE-HN: A Multicenter, Randomized, Placebo-Controlled, Phase 3 Study of Ficlatuzumab plus Cetuximab in Pts W/ Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma (HNSCC)

被引：0
|
作者：
Bauman, J. [1 ]
Allman, K. [2 ]
Haddad, R. I. [3 ]
机构：
[1] George Washington Univ, Sch Med & Hlth Sci, Med Oncol, Washington, DC USA
[2] AVEO Oncol, Boston, MA USA
[3] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 120卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3609
引用
收藏
页码：E734 / E734
页数：1
相关论文
共 50 条
  • [31] Active8: A randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with motolimod immunotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
    Cohen, E.
    Saba, N. F.
    Gitlitz, B.
    Haddad, R.
    Sukari, A.
    Neupane, P.
    Morris, J. C.
    Misiukiewicz, K.
    Manjarrez, K. L.
    Dietsch, G. N.
    Bryan, J. K.
    Hershberg, R. M.
    Ferris, R. L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [32] Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Safety results of a phase I/II study
    Chung, Christine
    Bonomi, Marcelo
    Steuer, Conor
    Schell, Michael
    Li, Jiannong
    Johnson, Matthew
    McMullen, Caitlin
    Wadsworth, J. Trad
    Patel, Krupal
    Kish, Julie
    Muzaffar, Jameel
    Kirtane, Kedar
    Rocco, James
    Saba, Nabil
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [33] A randomized phase II study of cetuximab (C) every 2 weeks at either 500 or 750 mg/m2 for patients (Pts) with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC).
    Fury, M. G.
    Sherman, E. J.
    Lisa, D. M.
    Agarwal, N.
    Algazy, K. M.
    Brockstein, B.
    Langer, C. J.
    Lim, D.
    Mehra, R.
    Rajan, S. K.
    Jafri, N.
    Korte, S.
    Lipson, B.
    Yunus, F.
    Tanvetyanon, T.
    Smith-Marrone, S.
    Ng, K. K.
    Xiao, H.
    Haque, S.
    Pfister, D. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [34] PEMDA-HN, an open-label, phase II, randomized controlled study of danvatirsen plus pembrolizumab compared to pembrolizumab alone in recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC)
    Saba, N.
    Youssoufian, H.
    Cohen, E.
    Singh, J.
    Makris, L.
    Perdomini, M.
    MacIntyre, S.
    Denker, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S592 - S592
  • [35] Safety and efficacy of panitumumab (pmab) in HPV-positive (+) and HPV-negative (-) recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Analysis of the global phase III SPECTRUM trial
    Stoehlmacher-Williams, Jan
    Villanueva, Cristian
    Foa, Paolo
    Rottey, Sylvie
    Winquist, Eric
    Licitra, Lisa F.
    Davidenko, Irina
    Skladowski, Krzysztof A.
    Tahara, Makoto
    Faivre, Sandrine J.
    Oliner, Kelly S.
    Pan, Zhiying
    Bach, Bruce A.
    Vermorken, Jan Baptist
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [36] Outcome of Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Post-Immune Checkpoint Inhibitor (ICI) Treatment
    Park, J. C.
    Merkin, R. D.
    Wirth, L.
    Patel, M. J.
    Roberts, T. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E41 - E41
  • [37] A phase II study of pemetrexed (P) plus gemcitabine (G) in patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)
    Pfister, D. G.
    Haque, S.
    Stambuk, H.
    Lisa, D. M.
    Shen, R.
    Carlson, D.
    Fury, M. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck
    Daniel W. Bowles
    Neil Senzer
    Diana Hausman
    Scott Peterson
    Alex Vo
    Luke Walker
    Roger B. Cohen
    Antonio Jimeno
    Investigational New Drugs, 2014, 32 : 1197 - 1203
  • [39] A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck
    Bowles, Daniel W.
    Senzer, Neil
    Hausman, Diana
    Peterson, Scott
    Vo, Alex
    Walker, Luke
    Cohen, Roger B.
    Jimeno, Antonio
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (06) : 1197 - 1203
  • [40] VCN-01 plus durvalumab in subjects with recurrent/metastatic head & neck squamous cell carcinoma (R/M HNSCC): Phase I clinical trial
    Jove, M.
    Brana, I.
    Taberna, M.
    Hernando-Calvo, A.
    Brenes Castro, J.
    Garralda, E.
    Plana Serrahima, M.
    Manos Pujol, M.
    Capella, G.
    Alemany, R.
    Blasi, E.
    Blasco, C.
    Cascallo Piqueras, M.
    Nin, R. Mesia
    ANNALS OF ONCOLOGY, 2019, 30 : 47 - 47
12345